Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease

Lifestyle modifications are the main support of nonalcoholic fatty liver disease (NAFLD) therapy. Weight loss is one of the primary goals in NAFLD, but the effects of different calorie-restricted diets remain unclear. Thus, we evaluated the effects of two calorie-restricted diets-the Mediterranean diet (Med diet) and low-fat diet-on liver status, cardiometabolic markers, and fatty acid profiles in patients with NAFLD. Twenty-four overweight/moderately obese men were randomly assigned to consume one of these diets. Lipid levels, glucose, insulin, liver enzymes, steatosis, and fatty acid profiles of serum and erythrocytes phospholipids were assessed. After 3 months, all participants had a significant weight loss ( gt 9%), with improvements in waist circumference, body fat %, index of visceral adiposity (VAI), lipid accumulation product, fatty liver (FLI), and hepatic steatosis (HSI) index (p lt 0.001). Both diets significantly lowered triglycerides, total and LDL-cholesterol, liver enzymes, fasting glucose, insulin, and HOMA-IR index. Fatty acid profiles were enhanced after both diets, with a significantly decreased n-6/n-3 ratio. Participants on the Med diet had higher levels of HDL-cholesterol and monounsaturated and n-3 docosahexaenoic acids in serum phospholipids and lower levels of saturated fatty acids, triglycerides, TG/HDL ratio, and FLI when compared to participants on the low-fat diet. Our results indicate that dietary patterns and calorie restriction represent central therapeutic issues in the improvement of obesity-related cardiometabolic alterations that are involved in the mechanism of hepatic steatosis. The Med diet may contribute to disease treatment even more than the low-fat diet since it leads to decreased saturated and increased monounsaturated and n-3 polyunsaturated fatty acid status and improved FLI in NAFLD patients

Using Transcranial Electrical Stimulation to modulate gambling-related cognitive functions: A systematic review and study protocol

Gambling represents a reward-based activity that many people engage in for fun and leisure. However, excessive gambling may lead to Gambling Disorder (GD), the most prevalent behavioural addiction. There is evidence that neural circuits behind some of the cognitive processes that drive GD can be modulated by Transcranial Electrical Stimulation (tES). To comprehensively understand the potential of tES in targeting cognitive mechanisms implicated in GD, we conducted a PRISMA-guided systematic review of studies that applied tES to modulate gambling-related cognitive processes in a diverse range of population samples, including healthy participants, participants with GD, as well as other addictions. Most of the studies used transcranial direct current stimulation (tDCS) to target dorsolateral prefrontal cortex (DLPFC). While 70% of studies showed neuromodulatory effects, the results varied considerably depending on the stimulation parameters, sample characteristics, as well as outcome measures used. We noticed that studies predominantly focused on the DLPFC without providing a clear rationale, even though other brain regions have shown greater relevance to the cognitive functions affected in GD. Furthermore, we have identified a gap in the existing literature regarding the use of tES among participants with gambling-related issues. Based on these findings, we propose a study protocol for investigating the effects of tES on cognitive functions affected in GD, in a sample of at-risk gamblers. In a sham-controlled, parallel-group study we will use multichannel tDCS to modulate the activity of anterior cingulate cortex, due to its key role in gambling-related cognitive processes. The electrode montage will be optimized based on current flow modeling. We will test the effects on cognitive tasks measuring risk-taking, impulsivity, inhibition, and decision-making. In addition to at risk-gamblers, we will sample control participants with no gambling-related issues. This approach will enable us to examine whether and how this factor may determine the responsiveness to tES

Beneficial effects of pomegranate peel extract on plasma lipid profile, fatty acids levels and blood pressure in patients with diabetes mellitus type-2: A randomized, double-blind, placebo-controlled study

Pomegranate peel contains high levels of various phytochemicals. We evaluated the effects of pomegranate peel extract (PoPEx) consumption on plasma lipid profile, fatty acids (FA) level and blood pressure (BP) in patients with diabetes mellitus type 2 (DMT2). Thirty-seven subjects were recruited in this double blind, placebo controlled randomized trial. The study group (n = 19) received over 8 week's capsules containing PoPEx twice a daily, while the placebo group received placebo. Treatment with PoPEx induced a significant lowering of both systolic and diastolic BP. The plasma levels of triglycerides, low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (LDL-C/HDL-C), and HbA1c were significantly decreased, while the level of HDL-C was significantly increased, compared with placebo intake. Moreover, the PoPEX treatment significantly improved the plasma lipids fatty acids content. It is concluded that consumption of PoPEx in DMT2 subject had favourable effects on some metabolic parameters, BP, lipid profile and plasma lipid FA composition

Metabolically healthy obesity: is there a link with polyunsaturated fatty acid intake and status?

The aim of this study was to compare dietary intake and status of polyunsaturated fatty acids (PUFA) in plasma and erythrocyte phospholipids metabolically healthy and unhealthy, and obese and nonobese persons. Metabolic health status in 171 participants was defined according to criteria for metabolic syndrome. Obese and nonobese metabolically unhealthy persons (MUHO and MUHNO) had higher energy intake of n-6 PUFA (7.82 +/- 1.03 and 7.49 +/- 0.86) and lower intake of n-3 PUFA (0.60 +/- 0.12 and 0.62 +/- 0.11) compared to obese and nonobese metabolically healthy persons (MHO and MHNO) (5.92 +/- 0.63 and 5.72 +/- 0.67; 1.20 +/- 0.07 and 1.22 +/- 0.09, respectively) and a higher n-6/n-3 PUFA ratio. The plasma level of n-6 PUFA was lower in the MUHO and MUHNO groups (38.49 +/- 3.71 and 38.53 +/- 2.19) compared to MHNO (40.90 +/- 2.43), while n-3 PUFA status was lower in obese than in nonobese persons (3.58 +/- 0.79 and 3.50 +/- 1.02 vs. 4.21 +/- 0.80 and 4.06 +/- 1.15). The MHO group had a higher eicosapentaenoic/arachidonic acid ratio and estimated desaturase (SCD16, D6D) and elongase activity in plasma phospholipids compared to MHNO. The low intake of n-3 PUFA is directly associated with metabolic risk factors. These results indicated that obesity is closely associated with low levels of n-3 PUFA in plasma phospholipids, suggesting that dietary modifications including n-3 PUFA supplementation appear to be suitable therapeutic strategy in obese persons